Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 7/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.78 |
| ▸ | USP2 | O75604 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ozagrel SCHEMBL29153959 | 0.89 | TBXAS1 (0.92) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| SCHEMBL28609155 | 0.87 | TBXAS1 (0.80) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL4211 | 0.87 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL4210 | 0.87 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL582828 | 0.86 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL36183 | 0.86 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL582827 | 0.86 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL36182 | 0.86 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL1652693 | 0.86 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL28049244 | 0.86 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180104220-A1 | IMIDAZOLE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104220-A1 | IMIDAZOLE COMPOUND | MAPT, SLC10A2, SLC5A11 | TBXAS1 1000/4885CYP1A2 147/4885USP2 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.